EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Hold” by StockNews.com

StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) from a sell rating to a hold rating in a research report report published on Monday.

A number of other brokerages have also recently weighed in on EYPT. HC Wainwright reiterated a buy rating and issued a $25.00 price target on shares of EyePoint Pharmaceuticals in a research report on Tuesday, February 28th. Chardan Capital reaffirmed a buy rating and issued a $21.00 target price on shares of EyePoint Pharmaceuticals in a report on Friday, March 3rd.

EyePoint Pharmaceuticals Stock Up 6.2 %

NASDAQ EYPT opened at $2.57 on Monday. EyePoint Pharmaceuticals has a 1-year low of $2.19 and a 1-year high of $13.63. The company has a current ratio of 5.61, a quick ratio of 5.50 and a debt-to-equity ratio of 0.21. The stock’s 50 day moving average is $3.88 and its two-hundred day moving average is $5.00. The company has a market capitalization of $87.59 million, a price-to-earnings ratio of -0.94 and a beta of 1.03.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of EYPT. Essex Investment Management Co. LLC raised its holdings in shares of EyePoint Pharmaceuticals by 1.2% in the second quarter. Essex Investment Management Co. LLC now owns 279,850 shares of the company’s stock valued at $2,202,000 after buying an additional 3,259 shares during the last quarter. Bard Associates Inc. raised its stake in shares of EyePoint Pharmaceuticals by 33.4% in the second quarter. Bard Associates Inc. now owns 33,024 shares of the company’s stock worth $260,000 after acquiring an additional 8,270 shares during the last quarter. Verition Fund Management LLC lifted its position in shares of EyePoint Pharmaceuticals by 17.6% during the second quarter. Verition Fund Management LLC now owns 537,569 shares of the company’s stock worth $4,231,000 after purchasing an additional 80,351 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of EyePoint Pharmaceuticals by 18.1% during the second quarter. Point72 Asset Management L.P. now owns 1,219,699 shares of the company’s stock valued at $9,599,000 after purchasing an additional 186,899 shares during the last quarter. Finally, Levin Capital Strategies L.P. acquired a new stake in shares of EyePoint Pharmaceuticals in the fourth quarter valued at approximately $276,000. Institutional investors and hedge funds own 88.27% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

(Get Rating)

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.